AIM ImmunoTech (NYSE:AIM – Get Free Report) and LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.
Institutional & Insider Ownership
12.0% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by company insiders. Comparatively, 38.4% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
AIM ImmunoTech has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AIM ImmunoTech | $170,000.00 | 38.87 | -$28.96 million | ($0.31) | -0.29 |
| LENZ Therapeutics | N/A | N/A | -$124.65 million | ($4.77) | -4.44 |
AIM ImmunoTech has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for AIM ImmunoTech and LENZ Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AIM ImmunoTech | 0 | 0 | 2 | 0 | 3.00 |
| LENZ Therapeutics | 0 | 0 | 7 | 1 | 3.13 |
AIM ImmunoTech presently has a consensus target price of $2.75, suggesting a potential upside of 2,908.75%. LENZ Therapeutics has a consensus target price of $41.67, suggesting a potential upside of 96.73%. Given AIM ImmunoTech’s higher probable upside, research analysts clearly believe AIM ImmunoTech is more favorable than LENZ Therapeutics.
Profitability
This table compares AIM ImmunoTech and LENZ Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AIM ImmunoTech | -12,594.21% | -421.73% | -147.54% |
| LENZ Therapeutics | N/A | -58.48% | -55.50% |
Summary
LENZ Therapeutics beats AIM ImmunoTech on 8 of the 14 factors compared between the two stocks.
About AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.
